Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The impact of G9a-inhibitors in T-cell and Treg differentiation [ATAC-seq]

ABSTRACT: The impact of G9a-inhibitors in T-cell and Treg differentiation [ATAC-seq]

PROVIDER: PRJNA807689 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR18053711_1.fastq.gz	Fastqsanger.gz
	SRR18053711_2.fastq.gz	Fastqsanger.gz
	SRR18053712_1.fastq.gz	Fastqsanger.gz
	SRR18053712_2.fastq.gz	Fastqsanger.gz
	SRR18053713_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

The impact of G9a-inhibitors in T-cell and Treg differentiation

Project description:The impact of G9a-inhibitors in T-cell and Treg differentiation

| PRJNA807687 | ENA

The impact of G9a-inhibitors in T-cell and Treg differentiation [ATAC-seq]

Project description:As methyltransferase G9a has been implicated in immune cell differentiation we have assessed the role of G9a enzymatic inhibitors (UNC0642) in the differentiation of human naïve T-cells under different stimulation conditions.

2022-12-31 | GSE196903 | GEO

The impact of G9a-inhibitors in T-cell and Treg differentiation [RNA-Seq]

Project description:The impact of G9a-inhibitors in T-cell and Treg differentiation [RNA-Seq]

| PRJNA803925 | ENA

The impact of G9a-inhibitors in T-cell and Treg differentiation [RNA-Seq]

2022-12-31 | GSE196226 | GEO

Single-cell ATAC-Sequencing of adipose Treg cells

Project description:Systematic characterizations of adipose Treg subsets and their in vivo roles remain uncommon. The goal of this study is to reveal the heterogeneity and chromatin landscape of adipose Treg cells. Using single-cell ATAC-seq to map adipose Treg cells, we identified different adipose subsets. Strikingly, our scATAC-seq analysis revealed a strong enrichment of key transcription factor motifs, which may play function in fate specification. By gain and loss of function studies, we further demonstrated adipose Treg subsets display disparate physiologic influences. Our findings have important implications for understanding phenotypic diversity of tissue Tregs in vivo.

2021-07-15 | GSE147768 | GEO

The impact of G9a-inhibitors in T-cell and Treg differentiation

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-12-31 | GSE196904 | GEO

Impact of Tcf1/Lef1 deficiency on Treg cells

Project description:Impact of Tcf1/Lef1 deficiency on Treg cells

| PRJNA490202 | ENA

Impact of ERBB inhibitors on erythroid progenitors

Project description:Impact of ERBB inhibitors on erythroid progenitors

| PRJNA422526 | ENA

Single-cell ATAC-Sequencing of adipose Treg cells

Project description:Single-cell ATAC-Sequencing of adipose Treg cells

| PRJNA616335 | ENA

Change in transcriptome upon G9a knockdown in RD ERMS (Embryonal Rhabdomyosarcoma) cells

Project description:The Wnt signaling pathway is down-regulated in embryonal rhabdomyosarcoma (ERMS) and contributes to the block of myogenic differentiation. Epigenetic mechanisms leading to its suppression are unknown and could pave the way towards novel therapeutic modalities. In this study, we demonstrate that the lysine methyltransferase G9a suppresses the canonical Wnt signalling pathway by activating expression of the Wnt antagonist DKK1. Inhibition of G9a expression or activity reduced DKK1 expression and elevated canonical Wnt signalling resulting in myogenic differentiation in vitro and in vivo. Mechanistically, G9a impacted Sp1 and p300 enrichment at the DKK1 promoter in a methylation-dependent manner. The reduced tumor growth upon G9a deficiency was reversed by recombinant DKK1 or LGK974, which also inhibits Wnt signaling. Consistently, among thirteen drugs targeting chromatin modifiers, G9a inhibitors were highly effective in reducing ERMS cell viability. Together, our study demonstrates that ERMS cells are vulnerable to G9a inhibitors and suggest that targeting the G9a-DKK1--catenin node holds promise for differentiation therapy.

2020-12-16 | GSE142975 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data